Upgrade to SI Premium - Free Trial

RBC Capital Reiterates Outperform Rating on Biogen (BIIB)

June 5, 2024 6:11 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "With ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles